Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6630]

WCLC 2025: New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer

WCLC 2025: New research identifies IFITM3 as key driver of immunotherapy response in small cell lung cancer

WCLC 2025: Clinical trial suggests immunotherapy before surgery is a potential new treatment for rare cancer

WCLC 2025: Clinical trial suggests immunotherapy before surgery is a potential new treatment for rare cancer

First genetically engineered cancer model in naked mole rats developed

First genetically engineered cancer model in naked mole rats developed

WCLC 2025: First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery immunotherapy combination for patients with operable mesothelioma

WCLC 2025: First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery...

WCLC 2025: Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

WCLC 2025: Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell...

WCLC 2025: Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

WCLC 2025: Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant...

WCLC 2025: FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

WCLC 2025: FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced...

WCLC 2025: Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

WCLC 2025: Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

WCLC 2025: Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

WCLC 2025: Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following...

WCLC 2025: Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

WCLC 2025: Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease...

More from ecancer